A post-hoc analysis of the phase 3b JUMP trial found that ruxolitinib plus anemia supportive care maintained efficacy and reduced transfusion needs in patients with myelofibrosis.

A post-hoc analysis of the phase 3b JUMP trial assessed outcomes in patients with myelofibrosis and baseline anemia who were treated with ruxolitinib alongside anemia-supportive therapies, according ...

Most of us have seen a service dog or a therapy cat making the rounds and raising morale. However, can other pets also be ...

During a live event, Thomas LeBlanc, MD, MA, discussed the outcomes of the COMMANDS trial of luspatercept in myelodysplastic ...

New findings reveal that combining erythropoiesis-stimulating agents with ruxolitinib maintains efficacy in treating ...

In this week’s edition of The Prototype, we look at a big space stock IPO, Korea’s plan to dominate the world of robots, ...

Halia Therapeutics has completed the enrolment in its Phase IIa trial of HT-6184 (Ofirnoflast) in those with lower-risk myelodysplastic syndrome (MDS). The two-stage trial is designed to test the ...

Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies inspired by genetic resilience, today announced the completion of enrollment for its open-label Phase 2a ...

Optimal management of anemia due to End-Stage Renal Disease (ESRD) is a challenging task to physicians due to large inter-subject variability in response to Erythropoiesis Stimulating Agents (ESA). We ...

The Accessible Games Initiative was announced at the Game Developers Conference (GDC) by the ESA and representatives from the five founding member companies. It’s relatively rare for the game ...

If a person's anaemia is 'ESA resistant' (when the blood does not contain target haemoglobin levels despite usual doses of ESA, or needs increasingly higher doses to maintain haemoglobin concentration ...